Background Soft drugs are molecules that are purposefully designed to be rapidly metabolized (metabolically labile). In anesthesia, the soft drug is useful because it enables precise titration to effect and rapid recovery, which might allow swift and clear-headed recovery of consciousness and early home readiness. Propofol may cause delayed awakening after prolonged infusion. Propanidid and AZD3043 have a different metabolic pathway compared to propofol, resulting in a short-acting clinical profile. Fluorine imparts a variety of properties to certain medicines, including an enhanced absorption rate and improved drug transport across the blood-brain barrier. We hypothesized that the introduction of fluorine to the frame structure of propanidid and AZD3043 would further accelerate the swift and clear-headed recovery of consciousness. To test this hypothesis, we developed a series of fluorine-containing phenyl acetate derivatives. Methodology/Principal Findings Fluorine-containing phenyl acetate derivatives were synthesized, and their hypnotic potencies and durations of LORR following bolus or infusion administration were determined in mice, rats and rabbits. The metabolic half-lives in the blood of various species were determined chromatographically. In vitro radioligand binding and γ-aminobutyric acidA (GABAA) receptor electrophysiology studies were performed. Among the 12 synthesized fluorine-containing phenyl acetate derivatives, compound 5j induced comparable duration of LORR with AZD3043, but more rapid recovery than AZD3043, propanidid and propofol. The time of compound 5j to return to walk and behavioral recovery are approximately reduced by more than 50% compared to AZD3043 in mice and rats and rabbits. The HD50 of compound 5j decreased with increasing animal size. Conclusions/Significance The rapid recovery might make compound 5j suitable for precise titration and allow swift and clear-headed recovery of consciousness and early home readiness.
References
[1]
Egan TD (2009) Is Anesthesiology going soft? Trends in fragile pharmacology. Anesthesiology 111: 229–30. doi: 10.1097/aln.0b013e3181ae8460
[2]
Sneyd JR, Rigby-Jones AE (2010) New drugs and technologies, intravenous anaesthesia is on the move (again). Br J Anaesth 105: 246–54. doi: 10.1093/bja/aeq190
[3]
Trapani G, Altomare C, Sanna E, Biggio G, Liso G (2000) Propofol in anesthesia. Mechanism of action, structure activity relationships, and drug delivery. Curr Med Chem 7: 249–71. doi: 10.2174/0929867003375335
[4]
Wiard RP, Feldman PL, Collins H (2007) CNS 7056: a novel ultra-short-acting benzodiazepine. Anesthesiology 107: 60–6. doi: 10.1097/01.anes.0000267503.85085.c0
[5]
Cotten JF, Husain SS, Forman SA (2009) Methoxycarbonyletomidate: a novel rapidly metabolized and ultra-short-acting etomidate analogue that does not produce prolonged adrenocortical suppression. Anesthesiology 111: 240–9. doi: 10.1097/aln.0b013e3181ae63d1
[6]
Egan TD, Obara S, Jenkins TE, Jaw-Tsai SS, Amagasu S, et al. (2012) AZD-3043 a novel, metabolically liable sedative-hypnotic agent with rapid and predictable emergence from hypnosis. Anesthesiology 116: 1267–77. doi: 10.1097/aln.0b013e31825685a6
[7]
Conway CM, Ellis DB (1970) Propanidid. Br J Anaesth 42: 249–54. doi: 10.1093/bja/42.3.249
[8]
Christmas D (1984) Immune reaction to propanidid. Anaesthesia 39: 470–3. doi: 10.1111/j.1365-2044.1984.tb07318.x
[9]
Glen JB, Davies DS, Thomson DS, Scarth SC, Thompson AV (1979) an animal model for the investigation of adverse responses to i.v. anaesthetic agent and their solvents. Br J Anaesth 51: 819–27. doi: 10.1093/bja/51.9.819
[10]
Craig RM, Fawcett JP, Boulton DW, Tucker IG (1997) Formulation and evaluation of a propanidid hydroxypropyl-β-cyclodextrin solution for intravenous anaesthesia. Int J Pharmaceut 159: 191–6. doi: 10.1016/s0378-5173(97)00283-4
[11]
Hagmann WK (2008) The many roles for fluorine in medicinal chemistry. J Med Chem 51: 4360–9. doi: 10.1021/jm800219f
[12]
Filler R, Sara R (2009) Fluorine in medicinal chemistry: a century of progress and a 60-year retrospective of selected highlights. Future Med Chem 1: 777–91. doi: 10.4155/fmc.09.65
[13]
B？hm HJ, Banner D, Bendels S, Kansy M, Kuhn B, et al. (2004) Fluorine in medicinal chemistry. Chem Bio Chem 5: 637–43. doi: 10.1002/cbic.200301023
[14]
Zhou H, Meng XJ, Lv J, Yi P, Zheng J (1998) Synthesis of 3-methoxy-4-hydroxyphenylacetic acid. Chem Reagent 20: 314–314.
[15]
Anderson A, Belelli D, Bennett J, Bennett DJ, Buchanan KI, et al. (2001) α-Amino Acid Phenolic Ester Derivatives: Novel Water-Soluble General Anesthetic Agents Which Allosterically Modulate GABAA Receptors. J. Med. Chem 44: 3582–91. doi: 10.1021/jm010903i
[16]
Zolle IM, Berger ML, Hammerschmidt F, Hahner S, Schirbel A, et al. (2008) New selective inhibitors of steroid 11β-hydroxylation in the adrenal cortex: Synthesis and structure-activity relationship of potent etomidate analogues. J Med Chem 51: 2244–53. doi: 10.1021/jm800012w
[17]
Atucha E, Hammerschmidt F, Zolle I, Sieghart W, Berger ML (2009) Structure-activity relationship of etomidate derivatives at the GABAA receptor: Comparison with binding to 11b-hydroxylase. Bioorg. Med Chem Lett 19: 4284–7. doi: 10.1016/j.bmcl.2009.05.065
[18]
Chen Y, Wang S, Xu X, Liu X, Yu M, et al. (2013) Synthesis and Biological Investigation of Coumarin Piperazine (Piperidine) Derivatives as Potential Multireceptor Atypical Antipsychotics. J. Med. Chem 56: 4671–90. doi: 10.1021/jm400408r
[19]
Butini S, Gemma S, Campiani G, Franceschini S, Trotta F, et al. (2009) Discovery of a new class of potential multifunctional atypical antipsychotic agents targeting dopamine D3 and serotonin 5-HT1A and 5-HT2A receptors: Design, synthesis, and effects on behavior. J Med Chem 52: 151–69. doi: 10.1021/jm800689g
[20]
Chen Y, Xu XQ, Liu X, Yu MQ, Liu BF, et al. (2012) Synthesis and evaluation of a series of 2-substituted-5-thiopropylpiperazine (piperidine)-1,3,4-oxadiazoles derivatives as atypical antipsychotics. PLoS ONE 7: e35186. doi: 10.1371/journal.pone.0035186
[21]
Husain SS, Douglas ER (2012) Modifying Methoxycarbonyl Etomidate Inter-Ester spacer Optimizes In Vitro Metabolic Stability and In Vivo Hypnotic Potency and Duration of Action. Anesthesiology 117: 1027–36. doi: 10.1097/aln.0b013e31826d3bef
